Compare GRI & XWEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRI | XWEL |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.3M |
| IPO Year | N/A | N/A |
| Metric | GRI | XWEL |
|---|---|---|
| Price | $4.23 | $0.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $644.00 | N/A |
| AVG Volume (30 Days) | 225.4K | ★ 485.5K |
| Earning Date | 03-16-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $29,523,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.96 | $0.31 |
| 52 Week High | $333.20 | $1.42 |
| Indicator | GRI | XWEL |
|---|---|---|
| Relative Strength Index (RSI) | 74.09 | 21.26 |
| Support Level | $0.18 | $0.31 |
| Resistance Level | $5.82 | $0.44 |
| Average True Range (ATR) | 0.31 | 0.03 |
| MACD | 0.57 | -0.00 |
| Stochastic Oscillator | 61.50 | 4.88 |
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresSpa. XpresTest, Naples Wax Center and Treat. XpresSpa provides travelers with premium spa services, including massage, nail and skin care, as well as spa and travel products. Treat is a travel health and wellness brand that offers in-airport spa. XpresTest provides COVID-19 screening and diagnostic testing in partnership with the CDC. Naples Wax Center operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products.